Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials

References

• Merck Frosst Canada ltée. GARDASIL - Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine. Product Monograph. Kirkland: Merck Canada Inc.; Feb 2015 p. 62. accessed on February 13, 2019 [ En ligne]. Disponible: https://www.merck.ca/static/pdf/GARDASIL-PM_E.pdf
   Google Scholar
• Merck Canada Inc. Highlights of prescribing information [On line] [accessed 2019 Feb 13] https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf
   Google Scholar
• GlaxoSmithKline. CERVARIX® human papillomavirus vaccine types 16 and 18 (recombinant, AS04 adjuvanted) [On line]; 2008. [accessed 2019 Feb 13] https://ca.gsk.com/media/589880/cervarix.pdf
   Google Scholar
• Plotkin SA, Orenstein WA, Offit PA. Vaccines. 6th edn ed. Philadelphia, USA: Saunders Elsevier; 2012. p. 1550.
   Google Scholar
• Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, Nene BM, Esmy PO, Joshi S, Poli URR, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. Jan. 2016;17(1):67–77. doi:10.1016/S1470-2045(15)00414-3.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, Bhatla N, Nene BM, Shaw J, Poli URR, et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018 June;36(32Pt A):4783–91. doi:10.1016/j.vaccine.2018.02.087.
   PubMed Web of Science ®Google Scholar
• Widdice LE, Unger ER, Panicker G, Hoagland R, Callahan ST, Jackson LA, Berry AA, Kotloff K, Frey SE, Harrison CJ, et al. Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals. Vaccine. 2018;36(6):881–89. doi:10.1016/j.vaccine.2017.12.042.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Timing and spacing of immunobiologics [One line]. [accessed 2019 Feb 13] https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html
   Google Scholar
• World Health Organisation. Table 3: recommendations* for interrupted or delayed routine immunization - summary of WHO position papers [On line]. [accessed 2019 Feb 13] https://www.who.int/immunization/policy/Immunization_routine_table3.pdf
   Google Scholar
• Zhu F-C, Chen W, Hu Y-M, Hong Y, Li J, Zhang X, Zhang Y-J, Pan Q-J, Zhao F-H, Yu J-X, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled trial. Int J Cancer. 2014 Dec 1;135(11):2612–22. doi:10.1002/ijc.v135.11.
   PubMed Web of Science ®Google Scholar
• Gilca V, Sauvageau C, Boulianne N, De Serres G, Couillard M, Krajden M, Ouakki M, Murphy D, Trevisan A, Dionne M. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule. Hum Vaccines Immunother. 2014;10(8):2438–45. doi:10.4161/hv.29617.
   PubMed Web of Science ®Google Scholar
• Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial. Cancer Prev Res (Phila Pa). 2013 Nov;6(11):1242–50. doi:10.1158/1940-6207.CAPR-13-0203.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, Schiffman M, Rodriguez AC, Chanock S, Jimenez S, et al. Evidence for single-dose protection by the bivalent HPV vaccine-review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018 Jan 20;36:4774–82. doi:10.1016/j.vaccine.2017.12.078.
   PubMed Web of Science ®Google Scholar
• Ám R-S, Moreira ED, Restrepo JA, Lazcano-Ponce E, Cabello R, Silva A, Andrade R, Revollo F, Uscanga S, Victoria A, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Res Amst Neth. 2018;5:63–74. doi:10.1016/j.pvr.2017.12.004.
   PubMed Web of Science ®Google Scholar
• Pittman PR, Cavicchia MA, Kingsbury JL, Johnson NA, Barrera-Oro JG, Schmader T, Korman L, Quinn X, Ranadive M. Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed. Vaccine. 2014 Sept 3;32(39):5131–39. doi:10.1016/j.vaccine.2014.03.076.
   PubMed Web of Science ®Google Scholar
• Bai C, He J, Niu H, Hu L, Luo Y, Liu X, Peng L, Zhu B. Prolonged intervals during Mycobacterium tuberculosis subunit vaccine boosting contributes to eliciting immunity mediated by central memory-like T cells. Tuberc Edinb Scotl. 2018;110:104–11. doi:10.1016/j.tube.2018.04.006.
   PubMed Web of Science ®Google Scholar
• Albas A, Fontolan OL, Pardo PE, Bremer Neto H, Sartori A. Interval between first dose and booster affected antibody production in cattle vaccinated against rabies. J Venom Anim Toxins Incl Trop Dis. 2006 Sept 26;12(3):476–86. doi:10.1590/S1678-91992006000300010.
   Web of Science ®Google Scholar
• Schöndorf I, Schönfeld C, Nicolay U, Zent O, Banzhoff A. Response to tick-borne encephalitis (TBE) booster vaccination after prolonged time intervals to primary immunization with the rapid schedule. Int J Med Microbiol IJMM. 2006 May;296(Suppl 40):208–12. doi:10.1016/j.ijmm.2006.01.009.
   PubMed Web of Science ®Google Scholar
• Askling HH, Vene S, Rombo L, Lindquist L. Immunogenicity of delayed TBE-vaccine booster. Vaccine. 2012 jan 11;30(3):499–502. doi:10.1016/j.vaccine.2011.11.061.
   PubMed Web of Science ®Google Scholar
• Ott JJ, Wiersma ST. Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2013 Nov;17(11):e939–e944.
   PubMed Web of Science ®Google Scholar
• Jackson Y, Chappuis F, Mezger N, Kanappa K, Loutan L. High immunogenicity of delayed third dose of hepatitis B vaccine in travellers. Vaccine. 2007 Apr 30;25(17):3482–84. doi:10.1016/j.vaccine.2006.12.053.
   PubMed Web of Science ®Google Scholar
• Castiglione F, Mantile F, De Berardinis P, Prisco A. How the interval between prime and boost injection affects the immune response in a computational model of the immune system. Comput Math Methods Med. 2012;2012:842329. doi:10.1155/2012/842329.
   PubMed Web of Science ®Google Scholar
• Petersen LK, Restrepo J, Moreira ED, Iversen O-E, Pitisuttithum P, Van Damme P, Joura EA, Olsson S-E, Ferris D, Block S, et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. Papillomavirus Res Amst Neth. 2017 June;3:105–15. doi:10.1016/j.pvr.2017.03.002.
   PubMed Web of Science ®Google Scholar
• Smith LM, Brassard P, Kwong JC, Deeks SL, Ellis AK, Lévesque LE. Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an Ontario cohort of grade 8 girls. BMC Public Health. 2011 Aug 13;11:645. doi:10.1186/1471-2458-11-645.
   PubMed Web of Science ®Google Scholar
• Freeman AJH, Gamboa C, Darbinian JA, Littell RD, Torrente S. Disparities in human papillomavirus vaccine completion rates among females in an integrated health care system. Obstet Gynecol. 2018;132(3):717–23. doi:10.1097/AOG.0000000000002802.
   PubMed Web of Science ®Google Scholar
• Lefevere E, Theeten H, Hens N, De Smet F, Top G, Van Damme P. From non school-based, co-payment to school-based, free human papillomavirus vaccination in Flanders (Belgium): a retrospective cohort study describing vaccination coverage, age-specific coverage and socio-economic inequalities. Vaccine. 2015 Sept 22;33(39):5188–95. doi:10.1016/j.vaccine.2015.07.088.
   PubMed Web of Science ®Google Scholar
• Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later – an exploratory study. Hum Vaccines Immunother. 2018 Sept 25:1–5.
   PubMed Web of Science ®Google Scholar
• Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. Vaccine. 2018 Oct 9. Hum Vaccin Immunother. 2019;15(2):503–507.
   Google Scholar
• Trial C. Scientific evaluation of one or two doses of the bivalent or nonavalent prophylactic HPV vaccines [On line]. [accessed 2019 Feb 13] https://clinicaltrials.gov/ct2/show/NCT03180034?term=Kreimer&cond=HPV+Infection&rank=1. Vaccine. 2018 Nov 12;36(46):7017–7024.
   Google Scholar
• Panicker G, Rajbhandari I, Gurbaxani BM, Querec TD, Unger ER. Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types. J Immunol Methods. 2015 Feb;417:107–14. doi:10.1016/j.jim.2014.12.013.
   PubMed Web of Science ®Google Scholar